Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 373


Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers.

Westerhout CM, Fu Y, Lauer MS, James S, Armstrong PW, Al-Hattab E, Califf RM, Simoons ML, Wallentin L, Boersma E; GUSTO-IV ACS Trial Investigators.

J Am Coll Cardiol. 2006 Sep 5;48(5):939-47.


Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy).

James SK, Lindahl B, Timmer JR, Ottervanger JP, Siegbahn A, Stridsberg M, Armstrong P, Califf R, Wallentin L, Simoons ML.

Am J Cardiol. 2006 Jan 15;97(2):167-72. Epub 2005 Nov 21.


N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.

Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD; Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators.

Circulation. 2004 Nov 16;110(20):3206-12. Epub 2004 Nov 8.


Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy.

James SK, Lindbäck J, Tilly J, Siegbahn A, Venge P, Armstrong P, Califf R, Simoons ML, Wallentin L, Lindahl B.

J Am Coll Cardiol. 2006 Sep 19;48(6):1146-54. Epub 2006 Aug 28.


N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease.

Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, Stridsberg M, Venge P, Wallentin L.

J Am Coll Cardiol. 2003 Dec 3;42(11):1909-16.


[Prognosis in unstable coronary artery disease. Multimarker strategy is the best basis for the therapeutic choice].

James S, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Wallentin L.

Lakartidningen. 2004 Apr 22;101(17):1514-9, 1521-2. Swedish.


Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy.

James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A, Simoons ML, Topol EJ, Venge P, Wallentin L; GUSTO-IV-ACS Investigators.

J Am Coll Cardiol. 2003 Mar 19;41(6):916-24.


[N-terminal pro-brain natriuretic peptide (NT-proBNP) and ischemia modified albumin (IMA) in exercise induced ischemia in patients with stable coronary artery disease].

Piechota WN, Wierzbowski R, Piechota WT, Bejm J, Gielerak G.

Pol Arch Med Wewn. 2006 Jul;116(1):640-7. Polish.


N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes.

Galvani M, Ottani F, Oltrona L, Ardissino D, Gensini GF, Maggioni AP, Mannucci PM, Mininni N, Prando MD, Tubaro M, Vernocchi A, Vecchio C; Italian Working Group on Atherosclerosis, Thrombosis, and Vascular Biology and the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO).

Circulation. 2004 Jul 13;110(2):128-34. Epub 2004 Jun 14.


Clinical correlation of multiple biomarkers for risk assessment in patients with acute coronary syndrome.

Narain VS, Gupta N, Sethi R, Puri A, Dwivedi SK, Saran RK, Puri VK.

Indian Heart J. 2008 Nov-Dec;60(6):536-42.


Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction.

Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, Vago L, Pasqualini F, Signorini S, Soldateschi D, Tarli L, Schweiger C, Fresco C, Cecere R, Tognoni G, Mantovani A; Lipid Assessment Trial Italian Network (LATIN) Investigators.

Circulation. 2004 Oct 19;110(16):2349-54. Epub 2004 Oct 11.


Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome.

Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B.

J Am Coll Cardiol. 2009 Jul 21;54(4):357-64. doi: 10.1016/j.jacc.2009.03.056.


A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes.

Ndrepepa G, Braun S, Mehilli J, Niemöller K, Schömig A, Kastrati A.

Clin Res Cardiol. 2007 Jan;96(1):30-7. Epub 2006 Oct 30.


N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes.

Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K.

Circulation. 2002 Dec 3;106(23):2913-8.


N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.

Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P.

JAMA. 2005 Apr 6;293(13):1609-16.


N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission.

Weber M, Bazzino O, Navarro Estrada JL, Fuselli JJ, Botto F, Perez de Arenaza D, Möllmann H, Nef HN, Elsässer A, Hamm CW.

J Am Coll Cardiol. 2008 Mar 25;51(12):1188-95. doi: 10.1016/j.jacc.2007.11.054.


Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome.

Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, Park HS, Cho Y, Chae SC, Jun JE, Park WH.

Circ J. 2006 Nov;70(11):1379-84.

Items per page

Supplemental Content

Write to the Help Desk